

# Simon M Ametamey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9233422/publications.pdf>

Version: 2024-02-01

83  
papers

3,120  
citations

218381  
26  
h-index

168136  
53  
g-index

88  
all docs

88  
docs citations

88  
times ranked

3722  
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Imaging with PET. Chemical Reviews, 2008, 108, 1501-1516.	23.0	1,074
2	Radiosynthesis and preclinical evaluation of <sup>11</sup> C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. Journal of Nuclear Medicine, 2006, 47, 698-705.	2.8	132
3	Human PET studies of metabotropic glutamate receptor subtype 5 with <sup>11</sup> C-ABP688. Journal of Nuclear Medicine, 2007, 48, 247-52.	2.8	121
4	Silicon-Based Building Blocks for One-Step <sup>18</sup> F-Radiolabeling of Peptides for PET Imaging. Angewandte Chemie - International Edition, 2008, 47, 4922-4925.	7.2	103
5	<sup>18</sup> F-Radiolabeling of Aromatic Compounds Using Triarylsulfonium Salts. European Journal of Organic Chemistry, 2012, 2012, 889-892.	1.2	77
6	Fluorine-18 Click Radiosynthesis and Preclinical Evaluation of a New <sup>18</sup> F-Labeled Folic Acid Derivative. Bioconjugate Chemistry, 2008, 19, 2462-2470.	1.8	76
7	Synthesis and preclinical evaluation of a folic acid derivative labeled with <sup>18</sup> F for PET imaging of folate receptor-positive tumors. Journal of Nuclear Medicine, 2006, 47, 1153-60.	2.8	60
8	Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor. European Journal of Medicinal Chemistry, 2015, 92, 554-564.	2.6	56
9	Discovery of a High Affinity and Selective Pyridine Analog as a Potential Positron Emission Tomography Imaging Agent for Cannabinoid Type 2 Receptor. Journal of Medicinal Chemistry, 2015, 58, 4266-4277.	2.9	55
10	Organofluorosilanes as Model Compounds for <sup>18</sup> F-Labeled Silicon-Based PET Tracers and their Hydrolytic Stability: Experimental Data and Theoretical Calculations (PET=Positron Emission) Tj ETQq0 0 0 rgBT.7 Overlook 10 Tf 50	1.7	10
11	Evaluation of <sup>11</sup> C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk. Journal of Nuclear Medicine, 2018, 59, 698-703.	2.8	46
12	Radiolabeling and <i>in vitro</i> / <i>in vivo</i> evaluation of N-(1- <i>adamantyl</i> )- <i>o</i> -methoxy-4- <i>oxo</i> -1-phenyl-1,4-dihydroquinoline-3-carboxamide as a <sup>18</sup> F-labeled PET probe for imaging cannabinoid type 2 receptor. Journal of Neurochemistry, 2013, 126, 616-624.	1.3	43
13	Radiosynthesis and Preclinical Evaluation of 3- <i>Aza</i> -2- <sup>18</sup> F-fluorofolic Acid: A Novel PET Radiotracer for Folate Receptor Targeting. Bioconjugate Chemistry, 2013, 24, 205-214.	1.8	43
14	Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. Neurobiology of Aging, 2015, 36, 1619-1628.	1.5	41
15	<sup>64</sup> Cu- and <sup>68</sup> Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGA-Folate. Molecular Pharmaceutics, 2016, 13, 1979-1987.	2.3	41
16	Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system. Acta Pharmacologica Sinica, 2019, 40, 351-357.	2.8	39
17	Nucleophilic ring-opening of activated aziridines: A one-step method for labeling biomolecules with fluorine-18. Journal of Fluorine Chemistry, 2009, 130, 902-912.	0.9	38
18	Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque Imaging. Molecules, 2015, 20, 2081-2099.	1.7	37

#	ARTICLE	IF	CITATIONS
19	Novel chemoselective <sup>18</sup> F-radiolabeling of thiol-containing biomolecules under mild aqueous conditions. <i>Chemical Communications</i> , 2016, 52, 6083-6086.	2.2	35
20	Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 299-308.	0.5	35
21	<i>N</i> -Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present). <i>Expert Opinion on Therapeutic Patents</i> , 2020, 30, 743-767.	2.4	33
22	Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 123-149.	2.9	33
23	Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules. <i>International Journal of Cardiology</i> , 2014, 174, 503-515.	0.8	32
24	Discovery of a fluorinated 4-quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2. <i>Journal of Neurochemistry</i> , 2016, 138, 874-886.	2.1	31
25	Synthesis and biological evaluation of 18F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging. <i>European Journal of Medicinal Chemistry</i> , 2013, 70, 768-780.	2.6	30
26	Preclinical Evaluation of Benzazepine-Based PET Radioligands ( <i>R</i> - and ( <i>S</i> )- <sup>11</sup> C-Me-NB1 Reveals Distinct Enantiomeric Binding Patterns and a Tightrope Walk Between GluN2B- and $\beta$ -Receptor-Targeted PET Imaging. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1167-1173.	2.8	30
27	Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue. <i>European Journal of Medicinal Chemistry</i> , 2018, 145, 746-759.	2.6	28
28	Preclinical evaluation and test-retest studies of [18F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 128-137.	3.3	27
29	Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [ <sup>11</sup> C]RS-016 targeting CB2 in atherosclerosis. <i>Nuclear Medicine and Biology</i> , 2017, 47, 31-43.	0.3	26
30	Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor. <i>Journal of Nuclear Medicine</i> , 2019, 60, 259-266.	2.8	26
31	Structure-Affinity Relationships of 2,3,4,5-Tetrahydro-1H-3-benzazepine and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-amine Analogues and the Discovery of a Radiofluorinated 2,3,4,5-Tetrahydro-1H-3-benzazepine Congener for Imaging GluN2B Subunit-Containing N-Methyl-d-aspartate Receptors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 9450-9470.	2.9	26
32	Investigation of the chick embryo as a potential alternative to the mouse for evaluation of radiopharmaceuticals. <i>Nuclear Medicine and Biology</i> , 2015, 42, 226-233.	0.3	25
33	Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10287-10306.	2.9	25
34	Comparative Studies of Three Pairs of $\beta$ - and $\beta$ -Conjugated Folic Acid Derivatives Labeled with Fluorine-18. <i>Bioconjugate Chemistry</i> , 2016, 27, 74-86.	1.8	24
35	Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 407-420.	3.3	24
36	Quantitative positron emission tomography of <sup>18</sup> F-mGluR5 in rat brain with [ <sup>18</sup> F]PSS232 at minimal invasiveness and reduced model complexity. <i>Journal of Neurochemistry</i> , 2015, 133, 330-342.	2.1	23

#	ARTICLE	IF	CITATIONS
37	Radiation dosimetry of <sup>18</sup> F-AzaFol: A first in-human use of a folate receptor PET tracer. <i>EJNMMI Research</i> , 2020, 10, 32.	1.1	23
38	Structure-Activity Relationships of Fluorinated (E)-3-((6-Methylpyridin-2-yl)ethynyl)cyclohex-2-enone- <i>O</i> -methylxime (ABP688) Derivatives and the Discovery of a High Affinity Analogue as a Potential Candidate for Imaging Metabotropic Glutamate Receptors Subtype 5 (mGluR5) with Positron Emission Tomography (PET). <i>Journal of Medicinal Chemistry</i> , 2010, 53, 4009-4017.	2.9	22
39	Synthesis and Pharmacological Evaluation of Enantiomerically Pure GluN2B Selective NMDA Receptor Antagonists. <i>ChemMedChem</i> , 2018, 13, 1580-1587.	1.6	21
40	Dynamic changes in cerebral and peripheral markers of glutamatergic signaling across the human sleep-wake cycle. <i>Sleep</i> , 2019, 42, .	0.6	20
41	CD80 Is Upregulated in a Mouse Model with Shear Stress-Induced Atherosclerosis and Allows for Evaluating CD80-Targeting PET Tracers. <i>Molecular Imaging and Biology</i> , 2017, 19, 90-99.	1.3	19
42	Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 11165-11181.	2.9	19
43	Preclinical Development of <sup>18</sup> F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-D-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis. <i>Journal of Nuclear Medicine</i> , 2021, 62, 259-265.	2.8	19
44	Synthesis and Characterization of a C(6) Nucleoside Analogue for their vivo Imaging of the Gene Expression of Herpes Simplex Virus Type-1 Thymidine Kinase (HSV1 TK). <i>Chemistry and Biodiversity</i> , 2006, 3, 274-283.	1.0	18
45	Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor. <i>Pharmaceuticals</i> , 2014, 7, 339-352.	1.7	17
46	In vitro and in vivo evaluation of [ <sup>18</sup> F]-FDEGPECO as a PET tracer for imaging the metabotropic glutamate receptor subtype 5 (mGluR5). <i>NeuroImage</i> , 2011, 56, 984-991.	2.1	16
47	A first-in-man PET study of [ <sup>18</sup> F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1041-1051.	3.3	16
48	Pharmacokinetic properties of enantiomerically pure GluN2B selective NMDA receptor antagonists with 3-benzazepine scaffold. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2019, 172, 214-222.	1.4	15
49	Reduced uptake of [ <sup>11</sup> C]-ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimer's dementia. <i>Brain and Behavior</i> , 2020, 10, e01632.	1.0	14
50	First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)- <sup>11</sup> C-Me-NB1. <i>Journal of Nuclear Medicine</i> , 2021, , jnumed.121.262427.	2.8	14
51	Imaging the glutamate receptor subtypes—Much achieved, and still much to do. <i>Drug Discovery Today: Technologies</i> , 2017, 25, 27-36.	4.0	13
52	Fluorinated GluN2B Receptor Antagonists with a Benzazepine Scaffold Designed for PET Studies. <i>ChemMedChem</i> , 2018, 13, 1058-1068.	1.6	13
53	Chemoselective <sup>18</sup> F-incorporation into pyridyl acyltrifluoroborates for rapid radiolabelling of peptides and proteins at room temperature. <i>Chemical Communications</i> , 2020, 56, 723-726.	2.2	13
54	Noninvasive PET Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1467-1473.	2.8	12

#	ARTICLE	IF	CITATIONS
55	Radiosynthesis and evaluation of an <sup>18</sup> F- $\alpha$ -labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2018, 3, 1.	1.8	11
56	In vivo Imaging of Cannabinoid Type 2 Receptors: Functional and Structural Alterations in Mouse Model of Cerebral Ischemia by PET and MRI. <i>Molecular Imaging and Biology</i> , 2022, 24, 700-709.	1.3	11
57	Reduced <sup>18</sup> F-Folate Conjugates as a New Class of PET Tracers for Folate Receptor Imaging. <i>Bioconjugate Chemistry</i> , 2018, 29, 1119-1130.	1.8	10
58	Synthesis and In Vitro Evaluation of E- and Z-Geometrical Isomers of PSS232 as Potential Metabotropic Glutamate Receptors Subtype 5 (mGlu5) Binders. <i>Synthesis</i> , 2013, 45, 1877-1885.	1.2	8
59	Development and Evaluation of Novel PET Tracers for Imaging Cannabinoid Receptor Type 2 in Brain. <i>Chimia</i> , 2014, 68, 208.	0.3	8
60	Diastereomerically Pure (R)- and (S)- <sup>3</sup> -Aza-2- <sup>18</sup> F-Fluoro-5-Methyltetrahydrofolates Show Unprecedentedly High Uptake in Folate Receptor-Positive KB Tumors. <i>Journal of Nuclear Medicine</i> , 2019, 60, 135-141.	2.8	8
61	Synthesis and pharmacological evaluation of fluorinated benzo[7]annulen-7-amines as GluN2B-selective NMDA receptor antagonists. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 354-379.	0.5	8
62	Identification of a PET Radiotracer for Imaging of the Folate Receptor- $\beta$ : A Potential Tool to Select Patients for Targeted Tumor Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1475-1481.	2.8	8
63	Characterization in nonhuman primates of (R)-[ <sup>18</sup> F]OF-Me-NB1 and (S)-[ <sup>18</sup> F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , 1.	3.3	8
64	Synthesis and Structure-Affinity Relationship of Small Molecules for Imaging Human CD80 by Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8090-8100.	2.9	7
65	Recent progress in allosteric modulators for GluN2A subunit and development of GluN2A-selective nuclear imaging probes. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 552-560.	0.5	7
66	Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and $\beta$ 1 receptor antagonists: Synthesis, receptor affinity, selectivity and antiallosteric activity. <i>European Journal of Medicinal Chemistry</i> , 2019, 177, 47-62.	2.6	7
67	[ <sup>11</sup> C]mHED PET follows a two-tissue compartment model in mouse myocardium with norepinephrine transporter (NET)-dependent uptake, while [ <sup>18</sup> F]LMI1195 uptake is NET-independent. <i>EJNMMI Research</i> , 2020, 10, 114.	1.1	7
68	Comparison of three novel radiotracers for GluN2B-containing NMDA receptors in non-human primates: (R)-[ <sup>11</sup> C]NR2B-Me, (R)-[ <sup>18</sup> F]of-Me-NB1, and (S)-[ <sup>18</sup> F]of-NB1. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1398-1409.	2.4	7
69	Replacement of the Benzylpiperidine Moiety with Fluorinated Phenylalkyl Side Chains for the Development of GluN2B Receptor Ligands. <i>ChemMedChem</i> , 2018, 13, 2522-2529.	1.6	6
70	[ <sup>18</sup> F]Flurpiridaz: Facile and Improved Precursor Synthesis for this Next-Generation Cardiac Positron Emission Tomography Imaging Agent. <i>ChemMedChem</i> , 2020, 15, 1040-1043.	1.6	6
71	Prodrug Approach toward the Development of a PET Radioligand for Imaging the GluN2A Subunits of the NMDA Receptor. <i>Organic Letters</i> , 2021, 23, 4584-4587.	2.4	5
72	Neuroimaging with Radiopharmaceuticals Targeting the Glutamatergic System. <i>Chimia</i> , 2020, 74, 960-967.	0.3	5

#	ARTICLE	IF	CITATIONS
73	<i>In Vitro</i> and <i>In Vivo</i> Evaluation of <i>N</i> -(2-(4-(3-cyanopyridin-2-yl)piperazin-1-yl)ethyl)- <sup>11</sup> C-methoxybenzamide, a Positron Emission Tomography (PET) Radioligand for Dopamine D <sub>4</sub> Receptors, in Rodents. <i>Chemistry and Biodiversity</i> , 2014, 11, 1298-1308.	1.0	4
74	Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [ <sup>18</sup> F]PSS232 in the Rat Brain. <i>Pharmaceuticals</i> , 2018, 11, 83.	1.7	4
75	Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 3559-3567.	1.4	4
76	Rest/stress myocardial perfusion imaging by positron emission tomography with <sup>18</sup> F-Flurpiridaz: A feasibility study in mice. <i>Journal of Nuclear Cardiology</i> , 2023, 30, 62-73.	1.4	4
77	Synthesis and in vitro/in vivo pharmacological evaluation of [ <sup>11</sup> C]-ThioABP, a novel radiotracer for imaging mGluR5 with PET. <i>MedChemComm</i> , 2013, 4, 520.	3.5	3
78	Synthesis and Biological Evaluation of Quinoxaline Derivatives for <sup>PET</sup> Imaging of the <sup>NMDA</sup> Receptor. <i>Helvetica Chimica Acta</i> , 2017, 100, e1700204.	1.0	3
79	Unexpected reactivity of cyclic perfluorinated iodanes with electrophiles. <i>Chemical Communications</i> , 2018, 54, 8999-9002.	2.2	3
80	Automated cGMP-compliant radiosynthesis of [ <sup>18</sup> F]- <i>E</i> -PSS232 for brain PET imaging of metabotropic glutamate receptor subtype 5. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2018, 61, 30-37.	0.5	2
81	Radiation dosimetry of [ <sup>18</sup> F]-PSS232 a PET radioligand for imaging mGlu5 receptors in humans. <i>EJNMMI Research</i> , 2019, 9, 56.	1.1	2
82	Evaluation of 5 H-thiazolo[3,2- <i>c</i> ]pyrimidin-5-ones as Potential GluN2A PET Tracers. <i>ChemMedChem</i> , 2020, 15, 2448-2461.	1.6	2
83	Improved Syntheses of the mGlu5 Antagonists MMPEP and MTEP Using Sonogashira Cross-Coupling. <i>Pharmaceuticals</i> , 2018, 11, 24.	1.7	0